Recombinant Human Cytochrome P450 2D6 (LKM 1 hp)

Cytochrome P450 2D6 (CYP2D6) is an important member of the cytochrome P450 enzyme superfamily, which includes a wide range of monooxygenases. As a monooxygenase, cytochrome P450 enzymes are extensively involved in drug metabolism, as well as the synthesis of cholesterol, steroids, and other lipids. CYP2D6 is located in the endoplasmic reticulum and plays a crucial metabolic role for up to 20% of commonly prescribed drugs. Its substrates include a variety of medications such as the antidepressant amitriptyline, the antiarrhythmic drugs propafenone and sparteine, and the adrenergic blocker debrisoquine. Due to high polymorphism in this gene among individuals, certain alleles can significantly reduce the enzyme's activity, directly affecting drug metabolism rates and leading to different metabolizer phenotypes.

Among these, codeine, as an opioid analgesic, largely relies on CYP2D6 activity for its efficacy. In the body, codeine is metabolized by CYP2D6 through O-demethylation into morphine, a potent opioid agonist. Therefore, the analgesic effects and safety of codeine are significantly influenced by CYP2D6 activity. The polymorphism of CYP2D6 is a major factor affecting individual responses to codeine. In extensive metabolizers, CYP2D6 can quickly convert codeine into morphine, resulting in significant analgesic effects. However, for individuals with poor metabolism, the conversion process is less efficient, leading to lower morphine levels and reduced analgesic effects. Conversely, ultrarapid metabolizers may experience higher morphine concentrations, increasing the risk of adverse effects, including respiratory depression. Thus, alternative analgesics are recommended for patients with poor or ultrarapid CYP2D6 metabolism. Notably, besides codeine, CYP2D6 is also involved in the metabolism of other opioids. For instance, tramadol, hydrocodone, and oxycodone are partially metabolized by CYP2D6. Tramadol is converted into its active metabolite O-desmethyltramadol by CYP2D6, which has a stronger affinity for μ-opioid receptors than the parent drug. For poor CYP2D6 metabolizers, the analgesic effect of tramadol may be compromised, while ultrarapid metabolizers might experience stronger analgesic effects and side effects. The metabolism of hydrocodone yields hydromorphone, also produced by CYP2D6, although the impact of hydrocodone's metabolic status on its efficacy remains unclear. The metabolism of oxycodone involves its conversion to oxymorphone, and there is a potential influence of CYP2D6 metabolism on its efficacy, but related data are not entirely consistent.

Figure 1. Codeine Metabolic Pathway Linked to CYP2D6 (Source: Crews KR, et al. 2012)

CYP2D6 not only plays a crucial role in drug metabolism, but its expression and activity are also regulated by various factors. The enzyme's function is influenced by transcription, post-transcriptional modifications, translation, and epigenetic factors. Highly methylated DNA and histone modifications can inhibit CYP2D6 expression, while hepatocyte nuclear factor 4α regulates its expression by binding to direct repeat elements in the CYP2D6 promoter. Small heterodimer partner inhibits transcriptional activation mediated by hepatocyte nuclear factor 4α. The farnesoid X receptor agonist GW4064 can reduce CYP2D6 expression while increasing the expression of small heterodimer partner and its recruitment to CYP2D6. Genotype is a key factor in the differences in CYP2D6 expression and activity, with recent genome-wide association studies revealing multiple genes that regulate CYP2D6. Factors such as pregnancy, liver or kidney disease, smoking, and alcohol consumption have relatively minor effects on CYP2D6 activity. Additionally, CYP2D6 has been implicated in research as a major autoantigen in type 2 autoimmune hepatitis (AIH). By generating mouse models expressing CYP2D6, researchers can explore the immunopathogenesis of autoimmune liver injury. These studies suggest that CYP2D6 may trigger immune responses against self-proteins, leading to liver damage. These mouse models provide a valuable experimental platform for evaluating potential therapeutic approaches. In drug design and toxicity prediction, research on CYP2D6 also plays a crucial role. Given its involvement in the metabolism of various drugs, its high polymorphism may lead to individual differences in drug responses. Recent advances in mammalian CYP2D6 X-ray structures have made computational prediction techniques increasingly feasible, considering clinically relevant allele variants. These studies aid in the development of more personalized drug therapy regimens and reducing the risk of adverse reactions. Overall, CYP2D6 is a multifunctional enzyme of significant clinical relevance. Its importance in drug metabolism and high genetic variability makes a deeper understanding of its mechanisms an essential component of personalized medicine and drug development.

Cytochrome P450 2D6 Antigen (LKM 1 hp)
LKM-1 Human P450 2D6
Anti-LKM1 (Cytochrome P450 2D6)
P450 2D6 (LKM1) Antigen